India is the world’s largest supplier of generic medications and vaccines. The country also boasts a robust pharmaceutical infrastructure and a growing domestic market.
Among top industry players, Medsexporter manufactures active pharmaceutical ingredients and pharmaceutical products. Their portfolio includes drugs for cardiology, gastroenterology, and anti-infectives. Glenmark Pharmaceuticals is another major player, focusing on therapeutic areas such as diabetes and autoimmune disorders.
Medsexporter
Medsexporter is dedicated to ensuring that quality medicines are available for everyone. They offer a variety of products including generic drugs, branded pharmaceuticals, and biosimilars. They specialize in gastroenterology, cardiovascular health, diabetes, oncology, and pain management. Founded in 1984, the company is headquartered in Hyderabad, India and has three segments: Global Generics, Proprietary Products, and Pharmaceutical Services & Active Ingredients.
Their pharmaceutical development and manufacturing services help innovators meet their regulated starting material (RSM), drug substance (API), and drug product (dosage form) requirements with a broad range of capabilities. They recently installed a FlexFactory, a single-use manufacturing platform from GE Healthcare, to expand their biosimilars capability. This will allow them to make the shift from stainless steel to single-use technology and increase efficiency. This will also reduce production time and cost. As a result, they will be able to bring more drugs to market.
Cipla
Cipla offers a wide range of branded and generic pharmaceutical formulations, drug delivery systems and active pharmaceutical ingredients. The company’s product portfolio includes complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, and other key therapeutic segments. Cipla also produces biosimilars, a high-growth segment.
Cipla is a professionally managed company, and any change in promoters should have only a marginal impact on its operations, says Tushar Manudhane, an equity research analyst at Motilal Oswal Financial Services Ltd. “The company is generating good traction in North America and South Africa, driven by products that are challenging to manufacture,” he adds. The company has 47 manufacturing sites globally. Founded in 1935, Cipla has long been committed to making affordable medicines available around the world. Their low-cost version of Tamiflu during the avian flu pandemic has made a significant difference in the lives of many people.
Lupin
Lupin offers a comprehensive range of generic and branded medicines. Its branded products include antidiabetic medications, anticoagulants, antihypertensives, and more. Its capabilities include research, development, and manufacturing of complex pharmaceutical formulations. It is headquartered in Mumbai, India.
Lupin’s ICI product helps organizations automate document processes and streamline workflow. Its contract management system allows legal to retrieve documentation of a contract’s negotiation history faster, accelerating business and optimizing outcomes. It also provides powerful search and analytics features plus collaboration tools. This enables the organization to respond quickly and efficiently to customer needs. It also helps improve corporate planning and accelerate market growth by identifying potential new opportunities. This is especially useful in assessing drug and patent expiries, as well as geographies impacted. Moreover, it allows companies to identify business opportunities and target specific accounts. This way, they can stay one step ahead of the competition.
Biocon
Biocon offers a portfolio of products across four therapeutic areas. Their product portfolio includes both generic drugs and biosimilars. They also have a growing list of novel biologics. These include the virulence blockers for bacterial diarrheal diseases and biosimilars of Insulin Glargine and Trastuzumab.
In 2004, Biocon made a splash in the stock market with its successful IPO. They also opened Biocon Park, India’s first biotechnology hub, which was inaugurated by Dr APJ Abdul Kalam. Later, they built their first high-tech fermentation plant and launched PlaFractor, a special machine for producing enzymes.
Biocon is committed to environmental, social, and governance initiatives. They strive to reduce their energy consumption and water use, and they are focused on hiring a diverse workforce. They also provide internship opportunities for graduates and postgraduate students. These positions can help you develop a flexible skill set and earn course credits.
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals offers a broad portfolio of specialty and generic drugs. Its formulation business comprises branded and generic products across therapeutic areas including dermatology, respiratory, oncology, cardiovascular, and diabetes. It also manufactures and supplies active pharmaceutical ingredients.
In the US, the company has an approved Abbreviated New Drug Application (ANDA) for Famotidine tablets USP, 10 mg and 20 mg, and Cetirizine hydrochloride tablet USP, 5 mg and 10 mg (OTC). It also has an ANDA for Lansoprazole delayed-release capsules USP, 15 mg, and a generic version of Seretide Accuhaler in the US market.
In addition, Glenmark has established a global fully-integrated clinical-stage biotech subsidiary, Ichnos Sciences Inc. (Ichnos). This alliance combines the drug innovation capabilities of both companies to develop cutting-edge therapies for hematological malignancies and solid tumors. The company has three oncology molecules in clinical trials, with two receiving orphan drug designation.
Biophar Lifesciences
Biophar Lifesciences offers a wide range of pharmaceutical formulations. The company produces and markets soft gelatin capsules, tablets, syrups, and sachets. It also offers third-party manufacturing services and PCD pharma franchise business. The company has a team of experts who research and develop new products.
We helped a global biopharma manufacturer improve yield in its fermentation and primary recovery processes with a machine-learning model that optimized batch, asset, and human parameters without disruption to existing production systems or governance models. In less than a year, the site increased plant throughput by 40 percent and capacity of its quality lab by 50 percent. Deviations decreased by 80 percent, and repeat deviations were eliminated.
As technology and biology converge, biopharma organizations must reinvent their business models to deliver innovative, patient-centric treatments faster and generate new revenue streams. Harnessing data-driven solutions is not a panacea, but it is a crucial first step.
Sai Distributors
Sai Distributors is a well-known name in the industry for offering a vast array of Pharmaceutical Medicine. These medicines are processed by using high-quality ingredients that are procured from reliable vendors. They are offered in the market at reasonable rates and in a wide variety of packaging options.
The company’s state-of-the-art warehousing facility is designed to resist natural disasters and is very spacious in nature. It also has an acoustic system to ensure that employees can communicate with each other in a timely manner.
In order to support global big pharma clients with end-to-end drug metabolism and pharmacokinetics (DMPK) services, the company added 25,000 sq. ft. of labs and recruited new global talent. These additions will provide faster turnaround times for absorption, distribution, metabolism, excretion (ADME) screening and PK/PD studies on small molecules, PROTACs, molecular glues, and peptides.
Saffron Medicare
Saffron Medicare offers a range of innovative saffron products including threads, powder, extracts, and pastes. Their collection features the highest quality NON-GMO saffron in a variety of flavors and formats. The company also offers a range of health supplements that use saffron as a key ingredient. The company’s products are available in the UK and Australia.
Practices have until Sunday June 19th to install the upgrade to Saffron SP3 and complete their connection to Medicare Web Services technology via PRODA. Failure to do this will prevent your practice from being able to verify patient eligibility or transmit AIR notifications to Medicare Read More.